ProCE Banner Activity

ExpressPoints
Key Questions on PARP Inhibitors in Ovarian Cancer: Experts Evaluate the Latest Evidence

Slideset Download
Download this short summary slideset of key takeaway points from a live interactive discussion on the latest data on PARP inhibitors in the treatment of ovarian cancer.

Released: July 06, 2021

Expiration: July 05, 2022

No longer available for credit.

Share

Faculty

Prof Jonathan A. Ledermann

Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci

Professor of Medical Oncology
CRUK and UCL Cancer Trials Centre
UCL Cancer Institute
Honorary Consultant in Medical Oncology
Cancer Services
UCL Hospitals
London, United Kingdom

Frederik Marmé

Frederik Marmé, MD, PhD

Assistant Professor of Gynecology
Division of Gynecologic Oncology
Medical Faculty of Heidelberg
University of Heidelberg
Heidelberg, Germany

Prof Isabelle Ray-Coquard

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci

Professor of Medical Oncology
CRUK and UCL Cancer Trials Centre
UCL Cancer Institute
Honorary Consultant in Medical Oncology
Cancer Services
UCL Hospitals
London, United Kingdom

Frederik Marmé, MD, PhD

Assistant Professor of Gynecology
Division of Gynecologic Oncology
Medical Faculty of Heidelberg
University of Heidelberg
Heidelberg, Germany

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France